Director N Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings Inc (CERE) [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
reported an insider sale according to the latest SEC filings. Director N Coles has sold 50,000 shares of the company on March 4, 2024. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this SEC Filing .Over the past year, the insider has sold a total of 552,506 shares of Cerevel Therapeutics Holdings Inc and has not made any purchases of the stock. This recent sale continues a trend observed over the past year, where insider transactions have been predominantly sales. In the same period, there have been 27 insider sells and 6 insider buys among Cerevel Therapeutics Holdings Inc insiders. On the day of the insider's recent sale, shares of Cerevel Therapeutics Holdings Inc were trading at $41.01 each, placing the company's market capitalization at $7.500 billion.Cerevel Therapeutics Holdings Inc is focused on discovering and developing new therapies for neuroscience diseases, including Parkinson's disease, epilepsy,
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseGlobeNewswire
- Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan [Yahoo! Finance]Yahoo! Finance
- AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]Seeking Alpha
CERE
Earnings
- 11/1/23 - Beat
CERE
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- CERE's page on the SEC website